Results 11 to 20 of about 205,939 (352)
Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. [PDF]
, 2012 Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease ...
Devata, Sumana, Kim, Edward J
core +10 more sources
Collision of ductal adenocarcinoma and neuroendocrine tumor of the pancreas: a case report and review of the literature [PDF]
, 2017 Background: Simultaneous occurrence of exocrine and neuroendocrine tumors of the pancreas is very infrequent. We report a patient with an endocrine tumor in the pancreatic-duodenal area and extensive exocrine carcinoma involving the whole pancreas.
Blandamura, Stella +6 more
core +2 more sources
The molecular basis for ethnic variation and histological subtype differences in prostate cancer. [PDF]
, 2013 Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China.
Goldstein, Andrew S +2 more
core +1 more source
Pancreatic neuroendocrine tumors
Intractable & Rare Diseases Research, 2017 Pancreatic neuroendocrine neoplasms (pNENs) are a heterogeneous group of tumors including well differentiated pancreatic neuroendocrine tumors (pNETs) and neuroendocrine carcinomas (pNECs). The incidence of pNENs has increased over the past few decades.
Varas-Lorenzo, Modesto J. +2 more
openaire +7 more sources
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
, 2007 Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM +35 more
core +1 more source
Frontiers in Neuroendocrinology, 2001 Tumor markers used in the diagnosis and follow-up of patients with neuroendocrine tumors are in most instances not specific for a given tumor and circulate under normal conditions in the serum, making their use as an early diagnostic tool difficult (low sensitivity).
Lamberts, S.W.J. +2 more
openaire +2 more sources
Treatment options for PNET liver metastases. a systematic review [PDF]
, 2018 Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo +8 more
core +1 more source
Duodenal carcinoid tumour – a case report [PDF]
, 2020 Duodenal carcinoids are rare tumours of the small intestine with heterogenous clinical and pathological characteristics. The long-term prognosis is very good if discovered in the early stages.
Alexescu, Teodora Gabriela +7 more
core +2 more sources
Frontiers in Endocrinology, 2023 IntroductionAlthough appendicitis occurs in approximately 1:1000 pregnancies, appendiceal neuroendocrine neoplasm (ANEN) diagnosis during pregnancy is very rare.
Orit Twito +11 more
doaj +1 more source
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
Diagnostics, 2015 To date, empirical literature has generally been considered lacking in relation to neuroendocrine carcinomas (NECs), the highly malignant subgroup of neuroendocrine neoplasms.
Emma Elizabeth Ilett +5 more
doaj +1 more source